Liu H, Huang F, Zhang Y, Wu M, et al. Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial. Am J Hematol 2023 Jan 1. doi: 10.1002/ajh.26800.
PMID: 36588387